The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Evidence for the use of gilteritinib as post-transplant maintenance in R/R AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the use of gilteritinib as post-transplant maintenance in relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Levis highlights evidence of a clear benefit to continuing the drug after transplant. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is in the relapsed/refractory setting. As many know, gilteritinib has an indication in much of the world for the relapsed/refractory setting. If you get a patient in remission, you want to move them to allotransplant if possible. And the obvious, we’ve just talked about post-transplant maintenance with the drug. You want to continue the drug after transplant. Is there a benefit to this? Well, many patients who were bridged to transplant did resume the drug...
So this is in the relapsed/refractory setting. As many know, gilteritinib has an indication in much of the world for the relapsed/refractory setting. If you get a patient in remission, you want to move them to allotransplant if possible. And the obvious, we’ve just talked about post-transplant maintenance with the drug. You want to continue the drug after transplant. Is there a benefit to this? Well, many patients who were bridged to transplant did resume the drug. And while it was not a re-randomization as regulatory authorities would like, it does provide evidence that there’s a clear benefit to resuming the drug post-transplant as expected. So this is just sort of data that reassures practitioners, there’s some evidence that you should resume the drug after transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
